Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.270 -0.250 (-9.92%)
Streaming Delayed Price Updated: 1:30 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 423,191
Open 2.520
Bid (Size) 2.270 (14)
Ask (Size) 2.280 (3)
Prev. Close 2.520
Today's Range 2.260 - 2.535
52wk Range 1.100 - 6.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
New to The Street T.V. Broadcasting on Bloomberg Saturday Aug 30th. The episode features TON Strategy Company (NASDAQ: TONX), Laser Photonics (NASDAQ: LASE), Sullivan & Cromwell Senior M&A Partner Frank Aquila, and Mercurity Fintech (NASDAQ: MFH)
Via ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation
Via Investor Brand Network

Performance

YTD
-24.1%
-24.1%
1 Month
-21.2%
-21.2%
3 Month
-15.6%
-15.6%
6 Month
-0.9%
-0.9%
1 Year
+20.7%
+20.7%

More News

Read More
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Insights Ahead: NRX Pharmaceuticals's Quarterly Earnings
Via Benzinga
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem
Via NewMediaWire
NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem
Via TheNewswire.com
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
Via Investor Brand Network
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street
Via NewMediaWire
From Novel Therapies To Treat Suicidal Bipolar Depression To Launching A Network Of Clinics, NRx Pharmaceuticals Is Getting Attention On Wall Street
Via TheNewswire.com
Why Small-Cap Biotech NRx Pharmaceuticals Is Drawing Heavy Retail Buzz
Via Stocktwits
$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
Loop Industries (NASDAQ: LOOP) – Roth Capital Bullish, CEO & Board Buy Big as Twist™ Gains Global Traction – More Stocks Inside
Via AB Newswire
Topics Economy
New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation
Via ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression
Via Investor Brand Network
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals
Via ACCESS Newswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition
Via Investor Brand Network
Topics Intellectual Property
Actions to Remove Benzethonium Chloride from Ketamine Products in Favor of Safer and Superior Option in $750 Million Market, Projected to Reach $3.35 Billion by 2034: NRx Pharmaceuticals, Inc.
Via Get News
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride from Ketamine Products
Via Investor Brand Network
Topics Intellectual Property
New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green
Via ACCESS Newswire

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?
NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market
What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?
The current price of NRX Pharmaceuticals, Inc. - Common Stock is 2.270
When was NRX Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 08/29/25 01:30 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.